allergy immunotherapy


Also found in: Encyclopedia, Wikipedia.

allergy immunotherapy

Mentioned in ?
References in periodicals archive ?
As a scientific leader of allergy immunotherapy, we are committed to helping improve the lives of allergic patients.
SEATTLE -- Research findings presented at the 2008 American College of Allergy, Asthma and Immunology (ACAAI) Scientific Meeting revealed a significant cost savings associated with allergy immunotherapy (IT) in children with allergic rhinitis (AR).
ITI is also planning on initiating a Phase II study of JRC-LAMP-vax later this year and following that in 2014 with our first food allergy immunotherapy for peanut allergy, ARA-LAMP-vax.
Greer, a leading developer and provider of allergy immunotherapy products and services, has completed enrollment for its pivotal Phase III clinical trial designed to study the efficacy of sublingual-oral immunotherapy (SLIT) as a treatment for adults with allergic rhinoconjunctivitis caused by short ragweed pollen.
Rotskoff's training in allergy immunotherapy gives him the expertise to create antigen blends for every patient.
TOLAMBA(TM), a ragweed allergy immunotherapy in Phase 2; a therapy for non-Hodgkin's lymphoma (NHL) in Phase 2 and for metastatic colorectal cancer in Phase 1; and a therapy for hepatitis B also in Phase 1.
Most pets with atopic dermatitis do not receive allergy immunotherapy due to two previous requirements: (1) having the pet allergy tested, and (2) the need for frequent, long-term injections.
The approval of GRAZAX(R) is based on the results from the largest clinical trial program ever conducted within allergy immunotherapy, comprising six clinical trials and a total of more than 1,700 patients.
Greer, a leading developer and provider of allergy immunotherapy products and services, announced today that findings from its Phase I safety and dosing clinical trials in sublingual-oral immunotherapy have been published in the March issue of the Annals of Allergy, Asthma and Immunology.
Food and Drug Administration (FDA) has completed its review of the Investigational New Drug Application ("IND") filed for the allergy immunotherapy, JRC- LAMP-vax[sup.
COPENHAGEN, Denmark, January 6 /PRNewswire/ -- According to preliminary results from a new study (GT-07) announced today, ALK-Abello's ground-breaking tablet-based allergy immunotherapy treatment reduces rhino-conjunctivitis (hay fever) symptoms by 37%, whilst reducing the need for symptom relieving medication by 41% (compared with placebo).
Greer, a leading developer and provider of allergy immunotherapy products and services, announced today the launch of a Phase III randomized, double-blind, placebo-controlled clinical trial evaluating the efficacy of sublingual-oral immunotherapy (SLIT) in adults with allergic rhinoconjunctivitis caused by short ragweed pollen.

Full browser ?